Author(s):
Shubham Sharma, Sunil Gupta
Email(s):
shubham.skdm@gmail.com
DOI:
10.52711/0974-360X.2026.00284 
Address:
Shubham Sharma1, Sunil Gupta2
1School of Pharmacy, Mangalayatan University, Aligarh - 202146, India ORCID ID: 0000-0003-0295-7052.
2Mangalayatan Institute of Pharmaceutical Education and Research, Mangalayatan University, Aligarh - 202146, India ORCID ID: 0000-0002-0383-6220.
*Corresponding Author
Published In:
Volume - 19,
Issue - 5,
Year - 2026
ABSTRACT:
Nasal mucosa has a high blood perfusion rate in the nasal cavity, which increases the drug's absorption and bioavailability in the systemic circulation compared to other routes. We need to apply a bio-compatible mucoadhesive polymer to increase the retention period of in-situ gel with nasal mucosa. However, the objective of the present study was to formulate and evaluate in-situ nasal gel of oxymetazoline hydrochloride. This drug delivery technology has the potential to bypass the initial metabolism of the medication and thereby enhance its bioavailability. A total 10 in situ nasal gels were created by combining hydroxypropyl methylcellulose (HPMC K-100) and xanthan gum in various polymeric ratios. All gel formulations that were produced (F1–F10) had pH values between 5.5±0.008 to 6.0±0.002. The gels' spreadability ranged from 10.1±0.24 to 6.7±0.67g/cm/sec. All prepared gel compositions were found to have gelling temperature ranged from 33.2±0.41°C to 34.8±0.36°C, gelling time ranged from 4.0±0.41 s to 10.1±0.16 seconds and gel strengths ranging from 51.16±0.66 to 62.14± 0.58. The range of 130.34±0.57 to 211.75±1.35 centipoises was found for the viscosity of the different prepared gels. All manufactured gel formulations were found to have a drug concentration ranging from 97.54±0.43 to 99.68±0.83 percent. Oxymetazoline hydrochloride nasal gels F9 have a 99.98 % drug release rate in their in vitro diffusion drug release. According to the release order kinetics, all of the formulations—from F1 to F10—followed the Higuchi diffusion model, as evidenced by the correlation coefficients R2=0.986 and 0.937, respectively. The drug release investigations conducted in a controlled laboratory environment shown that the formulated substances were capable of releasing the drug for a duration of 10hours. Furthermore, all of the formulations exhibited a consistent adherence to the Higuchi kinetics model. The accelerated stability investigations demonstrated that the gels remained stable throughout the six-month testing period. The Differential Scanning Calorimetry (DSC) and X-ray Diffraction (XRD) tests indicated the absence of any interaction between the medication and polymer. Based on these findings, it can be inferred that in situ nasal gels have the potential to be used as drug delivery systems for oxymetazoline HCl. This can help overcome first-pass metabolism and boost the bioavailability of the drug.
Cite this article:
Shubham Sharma, Sunil Gupta. In-Situ Gel-Based Nasal Drug Delivery of Oxymetazoline Hydrochloride: A Mucoadhesive Approach. Research Journal Pharmacy and Technology. 2026;19(5):1986-4. doi: 10.52711/0974-360X.2026.00284
Cite(Electronic):
Shubham Sharma, Sunil Gupta. In-Situ Gel-Based Nasal Drug Delivery of Oxymetazoline Hydrochloride: A Mucoadhesive Approach. Research Journal Pharmacy and Technology. 2026;19(5):1986-4. doi: 10.52711/0974-360X.2026.00284 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2026-19-5-5
5. REFERENCES:
1. Glazener F, Blake K, Gradman M. Bradycardia, hypotension, and near-syncope associated with afrin (oxymetazoline) nasal spray. N Engl J Med. 1983; 309(12): 731-9. doi:10.1056/NEJM198309223091213
2. Çelik YS, Örenli B, Al-Mohaya M, Mesut B, Özsoy Y. Nasal in situ gels as a drug delivery system: An overview of literature and clinical studies. J Res Pharm. 2023; 27(5). doi:10.29228/jrp.471
3. Sharma S, Chaurasia L, Ul-Islam DM, Singhal DS. Topical drug delivery of polyherbal drugs entrapped gel with design and validation.
4. Thrush DN. Cardiac arrest after oxymetazoline nasal spray. J Clin Anesth. 1995; 7(6): 512-4.
5. Earle RR, Ramadevi M, Usha AL. An overview on hydrophilic three-dimensional networks: Hydrogels. Asian J Pharm Res. 2021; 11(1): 23-8.
6. Hasan S, Bhandari S, Sharma A, Garg P. Emulgel: A review. Asian J Pharm Res. 2021; 11(4): 263-8.
7. Ahmad W, Jawed R. Formulation and evaluation of Yohimbine HCl proliposomal gels. Asian J Pharm Res. 2022; 12(4): 302-6.
8. Ramesh Y, Teja KP, Santhi K, Saraswathi H, Neeharika P, Saideepthi B. Formulation and evaluation of Losartan loaded proliposomal gels. Int J Pharmametr Integr Biosci. 2017; 2(4): 173-8.
9. Gizurason S. The relevance of nasal physiology to the design of drug absorption studies. Adv Drug Deliv Rev. 1993; 11:329-47.
10. Saudagar R. Formulation development and evaluation of topical gel of Lisinopril Dihydrate. Sch Acad J Pharm. 2016; 5(7): 277-83.
11. Choudhary S, Kumar P, Pandit V, Ashawat MS. Mucoadhesive in situ nasal gel: A promising approach.
12. Sabale AS, Kulkarni AD, Sabale AS. Nasal in situ gel: novel approach for nasal drug delivery. J Drug Deliv Ther. 2020; 10(2-s):183-97.
13. Ning LL. Characteristics of ophthalmic in situ gel and issues in progress. Chin J New Drugs. 2007; 16:988-90.
14. Baghwan RR, Ambekar AW, Tamboli SS. Formulation, development and evaluation of in-situ periodontal gel containing ofloxacin. Res J Pharm Technol. 2021; 14(9): 4609-14.
15. Nandgude T, Thube R, Jaiswal N, Deshmukh P, Chatap V, Hire N. Formulation and evaluation of pH induced in-situ nasal gel of salbutamol sulphate. Int J Pharm Sci Nanotechnol. 2008; 1(2): 177-83.
16. Sherafudeen SP, Vasantha PV. Development and evaluation of in situ nasal gel formulations of loratadine. Res Pharm Sci. 2015; 10(6): 466-76.
17. Ramesh Y, Reddigari JRP, Kothapalli CB. Formulation and evaluation of tropicamide in-situ gels loaded solid lipid nanoparticles for ocular drug delivery. J Drug Deliv Ther. 2018; 8(2): 194-207.
18. Tiwari S, Singh S, Tripathi PK, Dubey CK. A review - Nanogel drug delivery system. Asian J Res Pharm Sci. 2015; 5(4): 253-5.
19. Kulkarni V, Jain N, Shinde R, Kamble S. Formulation and evaluation of antimicrobial gels using essential oils. Asian J Pharm Res. 2024; 14(2): 129-32.
20. Miller SC, Donovan MD. Effect of poloxamer 407 gel on the miotic activity of pilocarpine nitrate in rabbits. Int J Pharm. 1982; 12(2-3): 147-52.
21. Ahmed VA, Kumar HG, Paranjothy KLK, Khaleel M. Ophthalmic drug delivery of diclofenac potassium from different polymer formulations: In situ sol gels. Res J Pharm Dosage Forms Technol. 2009; 1(2): 158-61.
22. Sabale AS, Kulkarni AD, Sabale AS. Nasal in situ gel: novel approach for nasal drug delivery. J Drug Deliv Ther. 2020; 10(2-s): 183-97.
23. Shah RA, Mehta MR, Patel DM, Patel CN. Design and optimization of mucoadhesive nasal in situ gel containing sodium cromoglycate using factorial design. Asian J Pharm. 2011; 5(2).
24. Khatri U, Saini S, Bharkatiya M. Pharmaceutical considerations of nasal in-situ gel as a drug delivery system. Asian J Pharm Res Dev. 2021; 9(3): 94-103.
25. Vijay M, Parjanya K. Formulation and evaluation of in-situ gel of bromhexine hydrochloride for nasal delivery. Der Pharm Sin. 2012.
26. Dhalkar PV, Jagtap SS, Jadhav ST, Redkar MR, Karande BS. Formulation and evaluation of in situ gel model naproxen. Asian J Pharm Technol. 2019; 9(3): 204-7.
27. Majithiya RJ, Ghosh PK, Umrethia ML, Murthy RS. Thermoreversible-mucoadhesive gel for nasal delivery of sumatriptan. AAPS PharmSciTech. 2006;7: E80-E86.
28. Sherafudeen SP, Vasantha PV. Development and evaluation of in situ nasal gel formulations of loratadine. Res Pharm Sci. 2015; 10(6): 466-76.
29. Trupa K, Gandhi S, Nidhi P, Dhruvisha C, Kadiya MJ. Formulation and evaluation nasal in situ gel of rizatriptan. Int J Pharm Res Technol. 2019; 9(2): 49-64.
30. Saudagar RB, Khandbahale SV. Formulation development and evaluation of nasal in-situ gel of fluticasone propionate. Int J Curr Pharm Res. 2017; 9: 45-54.
31. Choi HG, Jung JH, Ryu JM, Yoon SJ, Oh YK, Kim CK. Development of in situ-gelling and mucoadhesive acetaminophen liquid suppository. Int J Pharm. 1998; 165(1): 33-44.
32. Aiwale BV, Chaudhari BP, Redasani VK. A review on polymers for in situ drug delivery system. Asian J Res Pharm Sci. 2024; 14(1): 77-80.
33. Bhadani R. Electrochemical synthesis of polyacrylamide hydrogels-metal nanoparticles composites. Asian J Res Chem. 2014; 7(6): 593-5.
34. HB N, Bakliwal S, Pawar S. In-situ gel: new trends in controlled and sustained drug delivery system. Int J PharmTech Res. 2010; 2(2): 1398-408.
35. Valavi MP, Tadavi SA, Shaikh A, Pawar SP. Review on in situ gel a novel drug delivery system. World J Pharm Pharm Sci. 2019; 8(2): 1288-309.
36. Khandagale PM, Rokade MM, Phadtare DG. Formulation development and evaluation of nasal in-situ gel of hydrocortisone. Asian J Pharm Technol. 2018; 8(2): 92-102.
37. Jug M, Bećirević-Laćan M. Influence of hydroxypropyl-β-cyclodextrin complexation on piroxicam release from buccoadhesive tablets. Eur J Pharm Sci. 2004; 21(2-3): 251-60.
38. Khode PD, Dongare PA. In situ gel: a review of pharmaceutical and biological evaluation and approaches. Res J Pharm Dosage Forms Technol. 2019; 11(3): 217-26.
39. Kumar AMS, Bharath N, Rao MDS, Venkatesh P, Hepcykalarani D, Prema R. A review on mucoadhesive drug delivery systems. Res J Pharm Dosage Forms Technol. 2019; 11(4): 280-7.
40. Kohda Y, Kobayashi H, Baba Y, Yuasa H, Ozeki T, Kanaya Y, et al. Controlled release of lidocaine hydrochloride from buccal mucosa-adhesive films with solid dispersion. Int J Pharm. 1997; 158(2): 147-55.
41. Islam, M. M., Kumar, M., Mujtaba, M. A., Elhassan, G. O., Abdoun, S., Misbah, M., ... & Khalid, M. (2025). Formulation Development, Box-Behnken Design-Based Optimization and Evaluation of Cisplatin-Loaded Chitosan Nanoparticles Embedded in Mucoadhesive Buccal Film for Targeted Oral Cancer Therapy. Journal of Pharmaceutical Innovation, 20(6), 276.
42. Tripathi, D., Mishra, S., Rai, A. K., Sahoo, J., Sharma, D. K., & Singh, Y. (2022). Curcumin-loaded hydrotropic solid dispersion topical gel development and evaluation: A greener approach towards Transdermal delivery of drugs. Current Green Chemistry, 9(1), 26-39.